Navigation Links
AKELA Pharma Inc. announces U.S. public offering and proposed listing
Date:10/15/2007

http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL

MONTREAL, Oct. 15 /PRNewswire-FirstCall/ - AKELA Pharma Inc., (TSX: AKL), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that it is undertaking a public offering in the United States of 5,250,000 shares of its common stock. Akela has granted the underwriters a 30-day option to purchase up to an additional 787,500 shares at the public offering price to cover over-allotments, if any. Proceeds from the offering will be used to further the research, development and expansion of Akela's product candidates and for other working capital and general corporate purposes.

Akela has applied to list its common shares on the NASDAQ(TM) Global Market under the symbol "AKLA." Akela's shares are currently listed on the Toronto Stock Exchange under the symbol "AKL."

Lazard Capital Markets LLC will act as the sole book-running manager for the offering. Oppenheimer & Co., Inc. and Broadpoint Capital, Inc. will act as co-managers for the offering. A copy of the preliminary prospectus may be obtained by contacting Lazard Capital Markets LLC at 30 Rockefeller Plaza, New York, New York 10020, Attention: Syndicate Department, 60th Floor, or by phone at (212) 632-6717.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Akela Pharma Inc.

Akela Pharma is an integrated drug development company focused on developing therapies for the growing multi-billion dollar inhalation and pain markets. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, growth hormone deficiencies and controlled substance abuse deterrent formulations.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of AKELA Pharma Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.


'/>"/>
SOURCE Akela Pharma Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. India to benefit from pharma companies move
2. South Africa Wins landmark case against pharmaceutical giants
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
5. Pharma cos must forge Strategic alliances
6. Jharkhand Pharmacies Refuse To Sell Viagra
7. Setting up a new pharmaceutical industry in India
8. Medicis Pharmaceutical company enters pediatric market
9. Supply of Radiopharmaceuticals Hampered by Attacks
10. Pharma majors gear to supply anti-anthrax drug
11. Pharmacies in for a dose of bitter medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon ... the signature product of her research center at Bio-Logic Aqua Research® Water Life ... and the greatest number of sufferers of blindness. “We think that Nature’s Tears® ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... rates are on the rise, say researchers presenting their work at the ... Canada. , “The combination of evaluating the patterns of change in concussion symptom ...
(Date:7/20/2017)... 20, 2017 (PRWEB) , ... ... ... a global provider of enterprise-grade IT operations analytics and application performance monitoring ... one of world’s largest healthcare services providers. , According to Peter Ohrenberger, ...
(Date:7/20/2017)... ... ... Team Type 1 Foundation, a nonprofit organization pursuing a global mission of ... up with a Microsoft Corp. employee-led hackathon team for the 2017 Microsoft One Week ... Type 1’s mission overlaps seamlessly with Microsoft’s mission to empower every person and every ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... FDAnews Webinar**, Aug. 9, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... inspections and boosting quality. , It’s known as the “CY2016 Annual FDA Medical ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... SARASOTA, Fla. , July 11, 2017  Dr. Echenberg, founder of ... Dilator therapy program to patients who suffer from painful intercourse and other ... vaginismus and vaginal atrophy due to menopause. ... VuVatech LLC ... Dilators , created by Sarasota, Florida -based start-up company, ...
(Date:7/10/2017)... , July 10, 2017  US medical equipment and ... 2021, according to Medical Equipment & Supplies: ... Freedonia Focus Reports. Continued increases in demand for medical ... of the population and supported by gains in disposable ... and supplies. New product introductions will also drive sales ...
(Date:7/10/2017)... 2017  BDI Group subsidiary Pathway Purchasing Network, ... organization serving specialty pharmacies, home infusion companies and ... significant, value-added member programs designed to help organizations ... and improve access and affordability for patients who ... Pathway has worked ...
Breaking Medicine Technology: